

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

SYH2070 INJECTION (A DOUBLE-STRANDED SMALL INTERFERING RNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that SYH2070 Injection (a double-stranded small interfering RNA (“**siRNA**”) drug) (the “**Product**”), a Class 1 new chemical drug independently developed by the Group, has obtained approval from the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the U.S. The Product also obtained approval from the National Medical Products Administration of the People’s Republic of China in September 2025 to conduct clinical trials in China.

The Product is an siRNA drug that achieves liver-targeted delivery through N-acetylgalactosamine (GalNAc) conjugation and targets Angiopoietin-like 3 (“**ANGPTL3**”) via subcutaneous administration, effectively reducing ANGPTL3 levels. Through sequence optimization and chemical modification strategies, the Product achieves a more sustained gene silencing effect, making it a potential candidate as an ultra-long-lasting siRNA drug for ANGPTL3 reduction. It is indicated for the treatment of hypertriglyceridemia or mixed hyperlipidemia and has the potential to effectively reduce the risk of elevated residual cholesterol levels.

Preclinical studies showed that the Product exhibited superior pharmacological activity and duration of efficacy compared to similar siRNA products, and demonstrated differentiated advantages, such as long-lasting therapeutic effects, good safety profile and high patient adherence, providing a promising clinical development value.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 9 October 2025

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.